Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial

Although intravenous glycoprotein IIb/IIIa inhibitors are beneficial in patients with acute coronary syndromes, prolonged oral IIb/IIIa inhibition might provide an additional reduction in recurrent events. Investigators at 888 hospitals in 29 countries enrolled 10 288 patients with acute coronary sy...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) N.Y.), 2000-07, Vol.102 (2), p.149-156
Hauptverfasser:	CANNON, C. P, MCCABE, C. H, ALEXANDER, J. C, SKENE, A, BRAUNWALD, E, WILCOX, R. G, LANGER, A, CASPI, A, BERINK, P, LOPEZ-SENDON, J, TOMAN, J, CHARLESWORTH, A, ANDERS, R. J
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Alanine - administration & dosage Alanine - adverse effects Anticoagulants - administration & dosage Aspirin - administration & dosage Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Coronary Disease - drug therapy Coronary Disease - mortality Double-Blind Method Female Follow-Up Studies Heparin - administration & dosage Humans Intracranial Hemorrhages - chemically induced Intracranial Hemorrhages - mortality Male Medical sciences Middle Aged Myocardial Infarction - drug therapy Myocardial Infarction - mortality Pharmacology. Drug treatments Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Pyrrolidines - administration & dosage Pyrrolidines - adverse effects Stroke - drug therapy Survival Analysis Thrombocytopenia - chemically induced Thrombocytopenia - mortality Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!